197 related articles for article (PubMed ID: 25838392)
1. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
[TBL] [Abstract][Full Text] [Related]
2. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Nonviral
Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
Front Immunol; 2021; 12():802705. PubMed ID: 35082789
[TBL] [Abstract][Full Text] [Related]
4. Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19
Pennell CA; Campbell H; Storlie MD; Bolivar-Wagers S; Osborn MJ; Refaeli Y; Jensen M; Viaud S; Young TS; Blazar BR
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521930
[TBL] [Abstract][Full Text] [Related]
5. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
Vera J; Savoldo B; Vigouroux S; Biagi E; Pule M; Rossig C; Wu J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Blood; 2006 Dec; 108(12):3890-7. PubMed ID: 16926291
[TBL] [Abstract][Full Text] [Related]
6. Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models.
Imai K; Takeuchi Y; Terakura S; Okuno S; Adachi Y; Osaki M; Umemura K; Hanajiri R; Shimada K; Murata M; Kiyoi H
Mol Cancer Ther; 2024 Mar; 23(3):381-393. PubMed ID: 37828726
[TBL] [Abstract][Full Text] [Related]
7. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
Foster JB; Choudhari N; Perazzelli J; Storm J; Hofmann TJ; Jain P; Storm PB; Pardi N; Weissman D; Waanders AJ; Grupp SA; Karikó K; Resnick AC; Barrett DM
Hum Gene Ther; 2019 Feb; 30(2):168-178. PubMed ID: 30024272
[TBL] [Abstract][Full Text] [Related]
8. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
Barrett DM; Liu X; Jiang S; June CH; Grupp SA; Zhao Y
Hum Gene Ther; 2013 Aug; 24(8):717-27. PubMed ID: 23883116
[TBL] [Abstract][Full Text] [Related]
9. Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells.
Eugene-Norbert M; Cuffel A; Riou G; Jean L; Blondel C; Dehayes J; Bisson A; Giverne C; Brotin E; Denoyelle C; Poulain L; Boyer O; Martinet J; Latouche JB
J Immunol Methods; 2024 Feb; 525():113603. PubMed ID: 38147898
[TBL] [Abstract][Full Text] [Related]
10. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Wang LC; Lo A; Scholler J; Sun J; Majumdar RS; Kapoor V; Antzis M; Cotner CE; Johnson LA; Durham AC; Solomides CC; June CH; Puré E; Albelda SM
Cancer Immunol Res; 2014 Feb; 2(2):154-66. PubMed ID: 24778279
[TBL] [Abstract][Full Text] [Related]
11. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia.
Zhang Q; Hresko ME; Picton LK; Su L; Hollander MJ; Nunez-Cruz S; Zhang Z; Assenmacher CA; Sockolosky JT; Garcia KC; Milone MC
Sci Transl Med; 2021 Dec; 13(625):eabg6986. PubMed ID: 34936380
[TBL] [Abstract][Full Text] [Related]
12. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes.
Rabinovich PM; Komarovskaya ME; Wrzesinski SH; Alderman JL; Budak-Alpdogan T; Karpikov A; Guo H; Flavell RA; Cheung NK; Weissman SM; Bahceci E
Hum Gene Ther; 2009 Jan; 20(1):51-61. PubMed ID: 19025415
[TBL] [Abstract][Full Text] [Related]
13. Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.
Zhong N; Ma Q; Gong S; Shi Y; Zhao L; Wang D; Zhou H; Liu N; Ye Y; Wang J; Liu L; Guo Z
Int Immunopharmacol; 2024 May; 134():112174. PubMed ID: 38703571
[TBL] [Abstract][Full Text] [Related]
14. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics.
Cripe TP; Hutzen B; Currier MA; Chen CY; Glaspell AM; Sullivan GC; Hurley JM; Deighen MR; Venkataramany AS; Mo X; Stanek JR; Miller AR; Wijeratne S; Magrini V; Mardis ER; Mendell JR; Chandler DS; Wang PY
Sci Adv; 2022 Jul; 8(28):eabm1890. PubMed ID: 35857488
[TBL] [Abstract][Full Text] [Related]
15. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Zammarchi F; Corbett S; Adams L; Tyrer PC; Kiakos K; Janghra N; Marafioti T; Britten CE; Havenith CEG; Chivers S; D'Hooge F; Williams DG; Tiberghien A; Howard PW; Hartley JA; van Berkel PH
Blood; 2018 Mar; 131(10):1094-1105. PubMed ID: 29298756
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.
O'Brien Gore C; Billman A; Hunjan S; Colebrook J; Choy D; Li W; Haynes J; Wade J; Hobern E; McDonald L; Papa S; Brugman M; Kordasti S; Montiel-Equihua C
Mol Ther Oncolytics; 2023 Dec; 31():100749. PubMed ID: 38075248
[TBL] [Abstract][Full Text] [Related]
17. Author Correction: Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains.
Gordon KS; Kyung T; Perez CR; Holec PV; Ramos A; Zhang AQ; Agarwal Y; Liu Y; Koch CE; Starchenko A; Joughin BA; Lauffenburger DA; Irvine DJ; Hemann MT; Birnbaum ME
Nat Biomed Eng; 2023 Apr; 7(4):599-602. PubMed ID: 36737667
[No Abstract] [Full Text] [Related]
18. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
19. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
20. New cell sources for T cell engineering and adoptive immunotherapy.
Themeli M; Rivière I; Sadelain M
Cell Stem Cell; 2015 Apr; 16(4):357-66. PubMed ID: 25842976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]